Should The NICE Cost-Effectiveness Range Be Lowered?

This question goes to the heart of the use of the cost per quality-adjusted life-year (QALY) in healthcare decision making. Download or View Article here. (Source: J.P. Raftery, University of Southhampton, 5/9/14).

You might also be interested in:

Value of a QALY for France 08/21/2020
New Study Examines Perspective and Costing in… 09/11/2020
Tufts Analyzes Cost-Effectiveness Analysis for 1974-2018 07/28/2020
Study: Zero Co-Pay Program Reduced Health Spending by 18% 06/17/2020
How is the QALY Performing Amid a Pandemic? 05/22/2020
The QALY and Value Assessment Frameworks in the Asia-Pacific Context 09/14/2020
Non-submissions to NICE on the Rise Much to the Chagrin of the NHS 09/04/2020